Reviewing Todos Medical (OTCMKTS:TOMDF) and PolyPid (NASDAQ:PYPD)

PolyPid (NASDAQ:PYPD) and Todos Medical (OTCMKTS:TOMDF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Valuation and Earnings

This table compares PolyPid and Todos Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$23.86 million	($12.64)	-0.27
Todos Medical	$12.23 million	0.00	-$43.31 million	N/A	N/A

PolyPid has higher earnings, but lower revenue than Todos Medical.

Insider & Institutional Ownership

26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares PolyPid and Todos Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-969.85%	-121.65%
Todos Medical	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations for PolyPid and Todos Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	0	0	1	0	3.00
Todos Medical	0	0	0	0	N/A

PolyPid presently has a consensus target price of $14.00, indicating a potential upside of 311.76%.

Risk and Volatility

PolyPid has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, Todos Medical has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.

Summary

PolyPid beats Todos Medical on 5 of the 8 factors compared between the two stocks.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About Todos Medical

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.